Neuro Biosci to buy stake in CLL Pharma
US Neuro Bioscience has signed an agreement to acquire a minimum of 75 per cent of the issued and outstanding share capital of CLL Pharma, a French company engaged in the business of reformulating drugs using its proprietary drug delivery technologies.